ZymoGenetics (NASDAQ: [[ticker:ZGEN]]), a Seattle biotech company, and partner Bristol-Myers Squibb said today that a drug they are co-developing for hepatitis C was able to kill the virus with minimal side effects in a small four-week study. The trial looked at pegylated interferon lambda on its own, or in combination with a standard ribavirin treatment. The full data was presented at the European Association for the Study of the Liver meeting in Copenhagen, Denmark.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
